Table of Contents
International Scholarly Research Notices
Volume 2015 (2015), Article ID 489547, 6 pages
http://dx.doi.org/10.1155/2015/489547
Research Article

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations

Cerexa, Inc., Oakland, CA 94612, USA

Received 13 February 2015; Accepted 16 April 2015

Academic Editor: Wladimir Sougakoff

Copyright © 2015 Tiffany R. Keepers et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Lagacé-Wiens, A. Walkty, and J. A. Karlowsky, “Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections,” Core Evidence, vol. 9, pp. 13–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Castanheira, S. E. Farrell, K. M. Krause, R. N. Jones, and H. S. Sader, “Contemporary diversity of β-lactamases among enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 833–838, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. R. K. Flamm, G. G. Stone, H. S. Sader, R. N. Jones, and W. W. Nichols, “Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value,” Journal of Chemotherapy, vol. 26, no. 6, pp. 333–336, 2014. View at Publisher · View at Google Scholar
  4. H. S. Sader, M. Castanheira, R. K. Flamm, D. J. Farrell, and R. N. Jones, “Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, pp. 1684–1692, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-I. Kang, M. K. Cha, S. H. Kim et al., “Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria,” International Journal of Antimicrobial Agents, vol. 43, no. 5, pp. 456–459, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Segatore, D. Setacci, M. Perilli et al., “Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex β-lactamase patterns including extended-spectrum enzymes,” International Journal of Antimicrobial Agents, vol. 23, no. 5, pp. 480–486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. S. Thomson and E. S. Moland, “Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 12, pp. 3548–3554, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. CLSI, “Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement,” CLSI Document M100-S23, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2013. View at Google Scholar
  9. CLSI, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, CLSI Document M07-A9, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 9th edition, 2012.
  10. T. R. Keepers, M. Gomez, C. Celeri, W. W. Nichols, and K. M. Krause, “Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing enterobacteriaceae and Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 9, pp. 5297–5305, 2014. View at Publisher · View at Google Scholar
  11. Y. Harada, Y. Morinaga, N. Kaku et al., “In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae,” Clinical Microbiology and Infection, vol. 20, no. 11, pp. O831–O839, 2014. View at Publisher · View at Google Scholar
  12. L. López-Cerero, E. Picón, C. Morillo et al., “Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates,” Clinical Microbiology and Infection, vol. 16, no. 2, pp. 132–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. V. H. Tam, K. R. Ledesma, K. T. Chang, T. Y. Wang, and J. P. Quinn, “Killing of Escherichia coli by β-lactams at different inocula,” Diagnostic Microbiology and Infectious Disease, vol. 64, no. 2, pp. 166–171, 2009. View at Publisher · View at Google Scholar · View at Scopus